NCT00650910 - Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2008

Primary Completion Date

July 10, 2009

Study Completion Date

July 10, 2009

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.

DRUG

Digoxin

0.5mg on Days 1 and 9

Trial Locations (4)

GSK Investigational Site, Albuquerque

GSK Investigational Site, Edmonton

GSK Investigational Site, Seodaemun-gu, Seoul

GSK Investigational Site, Seoul